The stock has demonstrated a strong upward trajectory, trading above all major moving averages including the 5-day, 20-day, 50-day, 100-day, and 200-day marks. Over the last five consecutive trading days, Laurus Labs has delivered a cumulative return of 4.26%, outperforming its sector by 1.01% on the day of the new high. This steady climb highlights the stock’s resilience amid a broader market environment where the Sensex experienced a decline of 0.36%, trading at 84,649.07 points after an initial positive opening.
Over the past year, Laurus Labs has recorded a remarkable performance with a return of 112.18%, significantly outpacing the Sensex’s 9.46% gain during the same period. The stock’s 52-week low was Rs.475.45, indicating a substantial appreciation in value over the last twelve months. This performance places Laurus Labs well ahead of many peers within the BSE500 index across multiple time frames including one year, three years, and three months.
Momentum building strong! This mid-cap from Pharmaceuticals & Biotechnology is on our MomentumNow radar. Other investors are catching on – will you join?
- Building momentum strength
- Investor interest growing
- Limited time advantage
Financially, Laurus Labs has exhibited strong operational efficiency. The company’s return on capital employed (ROCE) stands at 16.75%, reflecting effective utilisation of capital resources. The latest quarterly results reveal a net profit after tax (PAT) of Rs.194.97 crores, representing a growth of 882.7% compared to previous periods. Profit before tax (PBT) excluding other income reached Rs.242.77 crores, showing an increase of 1233.17%. Operating profit to interest ratio is notably high at 10.08 times, indicating robust earnings relative to interest expenses.
These financial outcomes have been consistent, with Laurus Labs declaring positive results for four consecutive quarters. The company’s net profit growth of 993.4% in the September quarter further emphasises its strong earnings momentum. Institutional holdings account for 37.63%, suggesting a significant presence of investors with substantial analytical capabilities and resources.
Despite the strong recent performance, the company’s operating profit has grown at an annual rate of 5.37% over the last five years, indicating a more moderate long-term growth trend. The valuation metrics show a ROCE of 14.9 and an enterprise value to capital employed ratio of 8.2, which is considered relatively high. However, the stock is trading at a discount compared to the average historical valuations of its peers. The price-to-earnings-to-growth (PEG) ratio stands at 0.2, reflecting the relationship between the stock’s price, earnings growth, and valuation.
Get the full story on Laurus Labs ! Our detailed research dives into fundamentals, sector comparison, technical analysis, and valuations for this Pharmaceuticals & Biotechnology mid-cap. Make informed decisions!
- Full research story
- Sector comparison done
- Informed decision support
In the context of the broader market, the Sensex is trading near its own 52-week high, currently 0.76% below the peak of 85,290.06 points. The index remains above its 50-day moving average, which itself is positioned above the 200-day moving average, signalling a generally bullish technical setup. Against this backdrop, Laurus Labs’ achievement of a new 52-week high stands out as a significant development within the Pharmaceuticals & Biotechnology sector.
Overall, Laurus Labs’ recent price milestone at Rs.1033.55 reflects a combination of strong earnings growth, efficient capital utilisation, and sustained positive momentum. The stock’s performance over the past year and its position relative to key moving averages underscore its notable presence in the mid-cap segment of the Indian equity market.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
